Want to join the conversation?
$BIIB 2Q15 Q&A: Flynn of Goldman Sachs asked a question about TECFIDERA out year trajectory in US. Tony commented that the company believes that market continues to move to orals and it has the best oral. BIIB believes that it can continue to add patients. It’s harder work at this point given where it is in the product lifecycle.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.